Activating mutations in the epidermal growth factor receptor (EGFR), affecting hotspots within exons that code for the tyrosine kinase domain, can be found in 10-40% of NSCLC patients, mostly in adenocarcinomas, with the higher frequency observed in Asian patients[1,2]. Here, EGFR is linked to adenocarcinoma.